SRAX Advances Web3 Transformation as DNA Holdings Venture Merger Moves Forward

SRAX US78472M1062

SRAX is accelerating its shift into Web3, with the merger negotiations with DNA Holdings Venture Inc. at the core. The transaction, first announced in May 2024, is expected to extend the Sequire platform with Web3 capabilities and would yield a listed vehicle showcasing direct access to Web3 projects for investors. As the deal awaits closing, the market is eyeing the next operational milestone.

• Merger with DNA Holdings Venture Inc. (planned since May 2024)
• Incorporation of Web3 technologies into the Sequire analytics platform
• DNA shareholders anticipated to own the majority following completion
• Next (unconfirmed) quarterly earnings date: May 17/18, 2026

The ongoing fusion with DNA Holdings Venture Inc. marks a turning point for SRAX. The objective is to create a publicly traded entity that gives investors direct exposure to Web3 projects. Upon completion, DNA shareholders are expected to hold a majority stake in SRAX?s equity.

At the heart of the plan is the integration of decentralized technologies into SRAX?s investor intelligence software, Sequire. The aim is to supply data and analyses for the decentralized ecosystem going forward. Whether this blend of traditional investor-relations practices and Web3 can truly yield a meaningful market edge remains contingent on meeting contractual terms and securing the remaining regulatory approvals.

Key Dates for Investors

Additional visibility into SRAX?s operating condition is anticipated mid-May. Current expectations place the next quarterly results release around May 17 or 18, 2026, though this date has not been officially confirmed. For market participants, it?s a crucial date to assess the company?s financial stability amid the ongoing restructuring.

This development unfolds amid a dynamic fintech landscape where the convergence of digital communications and crypto assets is increasingly prominent. For SRAX, the primary goal is to position Sequire as the interface linking companies with investors in the Web3 space.

The completion of the DNA Holdings merger remains the principal driver of the stock?s future valuation. Until a potential balance-sheet event in May, regulatory hurdles must be cleared to finalize the anticipated control shift and demonstrate the operational viability of the new strategy.